Abstract
The study by Jiang et al. [1] to determine the impact of laryngopharyngeal reflux disease (LPRD) on the clinical outcomes in hospitalized patients with novel coronavirus disease 2019 (COVID‐19) is first of its kind study in the literature. While available studies have mostly focused on the effect of cardiovascular comorbidities, the authors' work raises the concurrent gastrointestinal related issues in patients with COVID‐19.
| Original language | English |
|---|---|
| Pages (from-to) | 92-93 |
| Number of pages | 2 |
| Journal | Journal of Medical Virology |
| Volume | 93 |
| Issue number | 1 |
| Early online date | 10 Jun 2020 |
| DOIs | |
| Publication status | Published - 1 Jan 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Could melatonin be used in COVID‐19 patients with laryngopharyngeal reflux disease?'. Together they form a unique fingerprint.Press/Media
-
Study says inhalers OK to use amid COVID-19 concerns
Merchant, H., Hasan, S. S., Capstick, T., Razi Zaidi, S. T. & Kow, C. S.
7/07/20 → 13/07/20
13 items of Media coverage
Press/Media: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver